IL2 and amyotrophic lateral sclerosis: Importantly, in the context of ALS, tofacitinib also significantly lowered cytotoxicity of IL-2/IL-15-stimulated primary NK cells isolated from ALS participants and healthy controls, as well as cytokine levels.